-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The biopharmaceutical industry is a strategic emerging industry with the characteristics of high technological content, broad development prospects, and huge market potential.
It is becoming an important fulcrum for leveraging high-quality development
.
In recent years, all parts of the country have seized the opportunities for the development of the biopharmaceutical industry, incorporated the biopharmaceutical industry into the grand blueprint for future development, and strived to create a "new engine" for economic growth
.
The biopharmaceutical industry is also a strategic emerging industry that Yantai is focusing on.
After years of unremitting cultivation, the city’s biopharmaceutical industry has entered a golden period of rapid development.
It has gathered a group of Luye Pharmaceuticals, Rongchang Biological, Dongcheng Pharmaceutical, and Zhenghai Biological.
The core biopharmaceutical companies have seized the opportunity to promote the transformation and upgrading of the biopharmaceutical industry, and have also accumulated sufficient stamina for high-quality development
.
At present, Yantai City has formed a whole industry chain covering the R&D, manufacturing and circulation of biological medicines, chemical medicines, modern Chinese medicines, and medical devices
.
According to statistics, Yantai has a total of 55 companies in the biomedical field with sales revenue exceeding 100 million yuan, 13 companies exceeding 1 billion yuan, 5 companies are listed at home and abroad, and 6 companies are giants in the domestic pharmaceutical industry and commercial fields, with 3 tens of billions.
Class-level industrial parks are beginning to take shape
.
In addition, Yantai has a number of innovative drugs with international influence, including innovative products such as Jinyouli, Endu, Heparin Sodium, and Antai.
In the first half of 2021, a total of 4 innovative products in Yantai have been approved for marketing, including Vidicitor.
Monoclonal antibody, tetaxel for injection, risperidone sustained-release microsphere II, bevacizumab injection
.
Among them, "Taltazep" is the world's first approved innovative dual-target biological agent, "Vedicituzumab" is China's first self-developed innovative antibody-conjugated drug, "Risperidone Microspheres for Injection ( Ⅱ)” is China’s first globally registered modified and innovative microsphere preparation, and “bevacizumab injection” is the third Avastin biosimilar approved for marketing in China
.
2021 is the first year of the "14th Five-Year Plan".
In the face of new opportunities, Yantai City will make every effort to strengthen the biomedical industry chain, build a vertical industrial ecosystem, and further promote the high-quality development of the biomedical industry
.
In accordance with the layout principle of “coordinated linkage, intensive clustering, and characteristic development”, Yantai City will build a “1+3+X” biomedical industry spatial layout, namely, to create a life science innovation leading core area in the east, a high-end medical equipment cluster development area in the west, and a central area.
Life and health integration development demonstration zone, southern high-end API green carrying zone, and other "X" industrial parks
.
It is worth mentioning that the biomedical industry has the characteristics of high technology content, long development cycle, and high risk.
The advent of a new drug often requires years of repeated experiments and clinical trials, as well as a large amount of talent and capital investment
.
In order to encourage innovation, Yantai City has issued "Several Policies to Promote the High-Quality Development of the Biomedicine Industry".
The city will reward and support 33 sub-fields in nine major areas
.
In terms of supporting R&D innovation and industrialization, chemical drugs, biological products, and traditional Chinese medicines are supported at a rate of 40% of the single-variety clinical research and development costs, with a maximum of 30 million yuan for first-category new drugs and 15 million yuan for second-category new drugs
.
A maximum of 50 million yuan in single-variety funds will be given to the production of qualified new drugs in this city
.
According to the biomedical industry blueprint drawn by Yantai City, by 2023, the city will strive to exceed 200 billion yuan in revenue from the main business of the biomedical industry, of which high-end pharmaceutical equipment manufacturing accounts for more than 60%, and the biomedical industry ecosystem is basically sound.
The overall strength and innovation capabilities have risen sharply, becoming an internationally and domestically influential and competitive life science innovation model city
.
It is becoming an important fulcrum for leveraging high-quality development
.
In recent years, all parts of the country have seized the opportunities for the development of the biopharmaceutical industry, incorporated the biopharmaceutical industry into the grand blueprint for future development, and strived to create a "new engine" for economic growth
.
The biopharmaceutical industry is also a strategic emerging industry that Yantai is focusing on.
After years of unremitting cultivation, the city’s biopharmaceutical industry has entered a golden period of rapid development.
It has gathered a group of Luye Pharmaceuticals, Rongchang Biological, Dongcheng Pharmaceutical, and Zhenghai Biological.
The core biopharmaceutical companies have seized the opportunity to promote the transformation and upgrading of the biopharmaceutical industry, and have also accumulated sufficient stamina for high-quality development
.
At present, Yantai City has formed a whole industry chain covering the R&D, manufacturing and circulation of biological medicines, chemical medicines, modern Chinese medicines, and medical devices
.
According to statistics, Yantai has a total of 55 companies in the biomedical field with sales revenue exceeding 100 million yuan, 13 companies exceeding 1 billion yuan, 5 companies are listed at home and abroad, and 6 companies are giants in the domestic pharmaceutical industry and commercial fields, with 3 tens of billions.
Class-level industrial parks are beginning to take shape
.
In addition, Yantai has a number of innovative drugs with international influence, including innovative products such as Jinyouli, Endu, Heparin Sodium, and Antai.
In the first half of 2021, a total of 4 innovative products in Yantai have been approved for marketing, including Vidicitor.
Monoclonal antibody, tetaxel for injection, risperidone sustained-release microsphere II, bevacizumab injection
.
Among them, "Taltazep" is the world's first approved innovative dual-target biological agent, "Vedicituzumab" is China's first self-developed innovative antibody-conjugated drug, "Risperidone Microspheres for Injection ( Ⅱ)” is China’s first globally registered modified and innovative microsphere preparation, and “bevacizumab injection” is the third Avastin biosimilar approved for marketing in China
.
2021 is the first year of the "14th Five-Year Plan".
In the face of new opportunities, Yantai City will make every effort to strengthen the biomedical industry chain, build a vertical industrial ecosystem, and further promote the high-quality development of the biomedical industry
.
In accordance with the layout principle of “coordinated linkage, intensive clustering, and characteristic development”, Yantai City will build a “1+3+X” biomedical industry spatial layout, namely, to create a life science innovation leading core area in the east, a high-end medical equipment cluster development area in the west, and a central area.
Life and health integration development demonstration zone, southern high-end API green carrying zone, and other "X" industrial parks
.
It is worth mentioning that the biomedical industry has the characteristics of high technology content, long development cycle, and high risk.
The advent of a new drug often requires years of repeated experiments and clinical trials, as well as a large amount of talent and capital investment
.
In order to encourage innovation, Yantai City has issued "Several Policies to Promote the High-Quality Development of the Biomedicine Industry".
The city will reward and support 33 sub-fields in nine major areas
.
In terms of supporting R&D innovation and industrialization, chemical drugs, biological products, and traditional Chinese medicines are supported at a rate of 40% of the single-variety clinical research and development costs, with a maximum of 30 million yuan for first-category new drugs and 15 million yuan for second-category new drugs
.
A maximum of 50 million yuan in single-variety funds will be given to the production of qualified new drugs in this city
.
According to the biomedical industry blueprint drawn by Yantai City, by 2023, the city will strive to exceed 200 billion yuan in revenue from the main business of the biomedical industry, of which high-end pharmaceutical equipment manufacturing accounts for more than 60%, and the biomedical industry ecosystem is basically sound.
The overall strength and innovation capabilities have risen sharply, becoming an internationally and domestically influential and competitive life science innovation model city
.
